Forest, Cypress report milnacipran Phase III data

Forest (NYSE:FRX) and Cypress (NASDAQ:CYPB) said milnacipran met both co-primary composite endpoints in the Phase

Read the full 155 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE